Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
Clinical trial NCT05143099 · UNKNOWN
Trial details
- NCT number
- NCT05143099
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-01
- Primary completion
- 2022-12-12
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.